AIM ImmunoTech is trading 6.21% lower at $0.15, with no clear company-specific catalyst identified for October 23, 2026.
- Recent company announcements were dated October 7 and earlier, rather than released today.
- Biotech shares are also under pressure, with the XBI down 2.08% during the regular session. Sector weakness may be contributing to the decline, but available evidence does not establish a direct cause.